Cargando…

Escherichia coli Nissle 1917 Enhances Innate and Adaptive Immune Responses in a Ciprofloxacin-Treated Defined-Microbiota Piglet Model of Human Rotavirus Infection

Human rotavirus (HRV) infection is a major cause of gastroenteritis in children worldwide. Broad-spectrum antibiotic-induced intestinal microbial imbalance and the ensuing immune-metabolic dysregulation contribute to the persistence of HRV diarrhea. Escherichia coli Nissle 1917 (EcN), a Gram-negativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Michael, Husheem, Paim, Francine C., Langel, Stephanie N., Miyazaki, Ayako, Fischer, David D., Chepngeno, Juliet, Amimo, Joshua, Deblais, Loic, Rajashekara, Gireesh, Saif, Linda J., Vlasova, Anastasia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546683/
https://www.ncbi.nlm.nih.gov/pubmed/33789939
http://dx.doi.org/10.1128/mSphere.00074-21
_version_ 1784590236426174464
author Michael, Husheem
Paim, Francine C.
Langel, Stephanie N.
Miyazaki, Ayako
Fischer, David D.
Chepngeno, Juliet
Amimo, Joshua
Deblais, Loic
Rajashekara, Gireesh
Saif, Linda J.
Vlasova, Anastasia N.
author_facet Michael, Husheem
Paim, Francine C.
Langel, Stephanie N.
Miyazaki, Ayako
Fischer, David D.
Chepngeno, Juliet
Amimo, Joshua
Deblais, Loic
Rajashekara, Gireesh
Saif, Linda J.
Vlasova, Anastasia N.
author_sort Michael, Husheem
collection PubMed
description Human rotavirus (HRV) infection is a major cause of gastroenteritis in children worldwide. Broad-spectrum antibiotic-induced intestinal microbial imbalance and the ensuing immune-metabolic dysregulation contribute to the persistence of HRV diarrhea. Escherichia coli Nissle 1917 (EcN), a Gram-negative probiotic, was shown to be a potent immunostimulant and alleviated HRV-induced diarrhea in monocolonized gnotobiotic (Gn) piglets. Our goal was to determine how EcN modulates immune responses in ciprofloxacin (Cipro)-treated Gn piglets colonized with a defined commensal microbiota (DM) and challenged with virulent HRV (VirHRV). Cipro given in therapeutic doses for a short term reduced serum and intestinal total and HRV-specific antibody titers, while EcN treatment alleviated this effect. Similarly, EcN treatment increased the numbers of total immunoglobulin-secreting cells, HRV-specific antibody-secreting cells, activated antibody-forming cells, resting/memory antibody-forming B cells, and naive antibody-forming B cells in systemic and/or intestinal tissues. Decreased levels of proinflammatory but increased levels of immunoregulatory cytokines and increased frequencies of Toll-like receptor-expressing cells were evident in the EcN-treated VirHRV-challenged group. Moreover, EcN treatment increased the frequencies of T helper and T cytotoxic cells in systemic and/or intestinal tissues pre-VirHRV challenge and the frequencies of T helper cells, T cytotoxic cells, effector T cells, and T regulatory cells in systemic and/or intestinal tissues postchallenge. Moreover, EcN treatment increased the frequencies of systemic and mucosal conventional and plasmacytoid dendritic cells, respectively, and the frequencies of systemic natural killer cells. Our findings demonstrated that Cipro use altered immune responses of DM-colonized neonatal Gn pigs, while EcN supplementation rescued these immune parameters partially or completely. IMPORTANCE Rotavirus (RV) is a primary cause of malabsorptive diarrhea in children and is associated with significant morbidity and mortality, especially in developing countries. The use of antibiotics exacerbates intestinal microbial imbalance and results in the persistence of RV-induced diarrhea. Probiotics are now being used to treat enteric infections and ulcerative colitis. We showed previously that probiotics partially protected gnotobiotic (Gn) piglets against human RV (HRV) infection and decreased the severity of diarrhea by modulating immune responses. However, the interactions between antibiotic and probiotic treatments and HRV infection in the context of an established gut microbiota are poorly understood. In this study, we developed a Gn pig model to study antibiotic-probiotic-HRV interactions in the context of a defined commensal microbiota (DM) that mimics aspects of the infant gut microbiota. Our results provide valuable information that will contribute to the treatment of antibiotic- and/or HRV-induced diarrhea and may be applicable to other enteric infections in children.
format Online
Article
Text
id pubmed-8546683
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-85466832021-11-04 Escherichia coli Nissle 1917 Enhances Innate and Adaptive Immune Responses in a Ciprofloxacin-Treated Defined-Microbiota Piglet Model of Human Rotavirus Infection Michael, Husheem Paim, Francine C. Langel, Stephanie N. Miyazaki, Ayako Fischer, David D. Chepngeno, Juliet Amimo, Joshua Deblais, Loic Rajashekara, Gireesh Saif, Linda J. Vlasova, Anastasia N. mSphere Research Article Human rotavirus (HRV) infection is a major cause of gastroenteritis in children worldwide. Broad-spectrum antibiotic-induced intestinal microbial imbalance and the ensuing immune-metabolic dysregulation contribute to the persistence of HRV diarrhea. Escherichia coli Nissle 1917 (EcN), a Gram-negative probiotic, was shown to be a potent immunostimulant and alleviated HRV-induced diarrhea in monocolonized gnotobiotic (Gn) piglets. Our goal was to determine how EcN modulates immune responses in ciprofloxacin (Cipro)-treated Gn piglets colonized with a defined commensal microbiota (DM) and challenged with virulent HRV (VirHRV). Cipro given in therapeutic doses for a short term reduced serum and intestinal total and HRV-specific antibody titers, while EcN treatment alleviated this effect. Similarly, EcN treatment increased the numbers of total immunoglobulin-secreting cells, HRV-specific antibody-secreting cells, activated antibody-forming cells, resting/memory antibody-forming B cells, and naive antibody-forming B cells in systemic and/or intestinal tissues. Decreased levels of proinflammatory but increased levels of immunoregulatory cytokines and increased frequencies of Toll-like receptor-expressing cells were evident in the EcN-treated VirHRV-challenged group. Moreover, EcN treatment increased the frequencies of T helper and T cytotoxic cells in systemic and/or intestinal tissues pre-VirHRV challenge and the frequencies of T helper cells, T cytotoxic cells, effector T cells, and T regulatory cells in systemic and/or intestinal tissues postchallenge. Moreover, EcN treatment increased the frequencies of systemic and mucosal conventional and plasmacytoid dendritic cells, respectively, and the frequencies of systemic natural killer cells. Our findings demonstrated that Cipro use altered immune responses of DM-colonized neonatal Gn pigs, while EcN supplementation rescued these immune parameters partially or completely. IMPORTANCE Rotavirus (RV) is a primary cause of malabsorptive diarrhea in children and is associated with significant morbidity and mortality, especially in developing countries. The use of antibiotics exacerbates intestinal microbial imbalance and results in the persistence of RV-induced diarrhea. Probiotics are now being used to treat enteric infections and ulcerative colitis. We showed previously that probiotics partially protected gnotobiotic (Gn) piglets against human RV (HRV) infection and decreased the severity of diarrhea by modulating immune responses. However, the interactions between antibiotic and probiotic treatments and HRV infection in the context of an established gut microbiota are poorly understood. In this study, we developed a Gn pig model to study antibiotic-probiotic-HRV interactions in the context of a defined commensal microbiota (DM) that mimics aspects of the infant gut microbiota. Our results provide valuable information that will contribute to the treatment of antibiotic- and/or HRV-induced diarrhea and may be applicable to other enteric infections in children. American Society for Microbiology 2021-03-31 /pmc/articles/PMC8546683/ /pubmed/33789939 http://dx.doi.org/10.1128/mSphere.00074-21 Text en Copyright © 2021 Michael et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Michael, Husheem
Paim, Francine C.
Langel, Stephanie N.
Miyazaki, Ayako
Fischer, David D.
Chepngeno, Juliet
Amimo, Joshua
Deblais, Loic
Rajashekara, Gireesh
Saif, Linda J.
Vlasova, Anastasia N.
Escherichia coli Nissle 1917 Enhances Innate and Adaptive Immune Responses in a Ciprofloxacin-Treated Defined-Microbiota Piglet Model of Human Rotavirus Infection
title Escherichia coli Nissle 1917 Enhances Innate and Adaptive Immune Responses in a Ciprofloxacin-Treated Defined-Microbiota Piglet Model of Human Rotavirus Infection
title_full Escherichia coli Nissle 1917 Enhances Innate and Adaptive Immune Responses in a Ciprofloxacin-Treated Defined-Microbiota Piglet Model of Human Rotavirus Infection
title_fullStr Escherichia coli Nissle 1917 Enhances Innate and Adaptive Immune Responses in a Ciprofloxacin-Treated Defined-Microbiota Piglet Model of Human Rotavirus Infection
title_full_unstemmed Escherichia coli Nissle 1917 Enhances Innate and Adaptive Immune Responses in a Ciprofloxacin-Treated Defined-Microbiota Piglet Model of Human Rotavirus Infection
title_short Escherichia coli Nissle 1917 Enhances Innate and Adaptive Immune Responses in a Ciprofloxacin-Treated Defined-Microbiota Piglet Model of Human Rotavirus Infection
title_sort escherichia coli nissle 1917 enhances innate and adaptive immune responses in a ciprofloxacin-treated defined-microbiota piglet model of human rotavirus infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546683/
https://www.ncbi.nlm.nih.gov/pubmed/33789939
http://dx.doi.org/10.1128/mSphere.00074-21
work_keys_str_mv AT michaelhusheem escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT paimfrancinec escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT langelstephanien escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT miyazakiayako escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT fischerdavidd escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT chepngenojuliet escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT amimojoshua escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT deblaisloic escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT rajashekaragireesh escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT saiflindaj escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection
AT vlasovaanastasian escherichiacolinissle1917enhancesinnateandadaptiveimmuneresponsesinaciprofloxacintreateddefinedmicrobiotapigletmodelofhumanrotavirusinfection